These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 23975660

  • 1. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ.
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():130-7. PubMed ID: 22552988
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
    Sallee FR, Kollins SH, Wigal TL.
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):206-14. PubMed ID: 22612526
    [Abstract] [Full Text] [Related]

  • 6. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [Abstract] [Full Text] [Related]

  • 7. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C, Haynes VS, Nyhuis A, Faries DE, Gelwicks S, Kelsey DK, Alatorre CI.
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
    Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.
    Eur Child Adolesc Psychiatry; 2017 Aug; 26(8):875-897. PubMed ID: 28258319
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H.
    J Clin Psychiatry; 2020 Apr 14; 81(3):. PubMed ID: 32297719
    [Abstract] [Full Text] [Related]

  • 10. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH.
    CNS Drugs; 2015 Nov 14; 29(11):953-62. PubMed ID: 26547425
    [Abstract] [Full Text] [Related]

  • 11. Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
    Shafrin J, Shrestha A, Chandra A, Erder MH, Sikirica V.
    Health Econ; 2017 Nov 14; 26(11):1459-1466. PubMed ID: 27620206
    [Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2013 Sep 14; 52(9):921-30. PubMed ID: 23972694
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.
    J Child Adolesc Psychopharmacol; 2009 Oct 14; 19(5):501-10. PubMed ID: 19877974
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
    Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D.
    CNS Drugs; 2013 Dec 14; 27(12):1081-92. PubMed ID: 23959815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.